Skip to content
ppharmaranks
Menu
Class IICompleted

Epinephrine Lidocaine HCL recall

FDA recall D-0535-2025 · initiated Jul 9, 2025

By the pharmaranks editorial teamReviewed against the FDA (openFDA) sourcesUpdated Jul 30, 2025How we research

Imprimis NJOF, LLC recalled Epinephrine Lidocaine HCL in Jul 2025 — an FDA Class II recall (D-0535-2025) because Sub-Potent Drug: Subpotent assay results during stability testing.

May cause temporary or medically reversible harm; low probability of serious harm.

Why it was recalled

Sub-Potent Drug: Subpotent assay results during stability testing.

Wrong strength, or it did not keep

The product did not contain what the label promised, or stopped meeting specification before its expiry date. Under-strength medicine can mean an untreated condition.

This is a manufacturing or quality failure, not a finding that the medicine is unsafe to take — across every recall we hold, none was issued for that reason. It does not mean the batch was harmless.

Is your product affected? Check the lot number

A recall covers only specific lots. Find the lot number and expiration date on your package and compare them to the affected codes below — if yours is not listed, it was not part of this recall.

Lot: 24DEC017, Exp. 07/12/2025.

Quantity recalled: 6,880 vials

Details

Product
Epinephrine Lidocaine HCL, 0.25mg/mL and 7.5 mg/mL, 20x1 mL Vials per carton, Rx Only, Imprimis NJOF, 1705 Route 46 West, Unit 6B Ledgewood, NJ, 07852 NDC: 71384-641-01
Recalling company
Imprimis NJOF, LLC
Classification
Class II
Status
Completed
Type
Voluntary: Firm initiated
Distribution
Nationwide in the USA
Initiated
Jul 9, 2025
FDA report date
Jul 30, 2025
What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.

Frequently asked

Was Epinephrine Lidocaine HCL recalled?
Imprimis NJOF, LLC recalled Epinephrine Lidocaine HCL in Jul 2025 — an FDA Class II recall (D-0535-2025) because Sub-Potent Drug: Subpotent assay results during stability testing. May cause temporary or medically reversible harm; low probability of serious harm.
Why was Epinephrine Lidocaine HCL recalled?
Per the FDA enforcement record, the reason for recall D-0535-2025 was: Sub-Potent Drug: Subpotent assay results during stability testing.
Is a recalled Epinephrine Lidocaine HCL dangerous to take?
An FDA recall removes specific lots from the market for a defined reason and does not by itself mean the medicine is unsafe for everyone — your specific lot may never have been affected. May cause temporary or medically reversible harm; low probability of serious harm. Check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This reproduces public FDA data and is not medical advice.
Which lots of Epinephrine Lidocaine HCL are affected?
Distributed: Nationwide in the USA. The recall covers these lots — Lot: 24DEC017, Exp. 07/12/2025.. Check the lot number and expiration date on your package against this list; if yours is not listed, it was not part of recall D-0535-2025.

Source: openFDA Drug Enforcement record D-0535-2025

← All drug recalls